Skip to main content

Oruka Therapeutics, Inc. (ORKA) Stock Analysis

SellVALUE-TRAP 1/5Moderate Confidence

Healthcare · Biotechnology

Sell if holding. Engine safety override at $58.56: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 7.5:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 18%; Below-average business quality; Negative price momentum.

Oruka Therapeutics is a clinical-stage biopharmaceutical company developing extended half-life monoclonal antibodies for psoriasis and other inflammatory conditions. Lead programs ORKA-001 (IL-23p19, Phase 2) and ORKA-002 (IL-17A/F, Phase 2) are licensed from Paragon... Read more

$58.56+112.0% A.UpsideScore 5.3/10#61 of 157 Biotechnology
QualityF-score4 / 9FCF yield-1.50%
Stop $55.79Target $123.69(analyst − 13%)A.R:R 7.5:1
Analyst target$142.17+142.8%12 analysts
$123.69our TP
$58.56price
$142.17mean
$200

Sell if holding. Engine safety override at $58.56: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 7.5:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 18%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.3/10, moderate confidence.

Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news boost analyst 0.70, earnings proximity 84d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.

Val9.0Qual1.5Grw5.0Mom3.4Sent8.6Ins3.8Peer5.8Tech7.5Risk4.35.3OVERALL

Recent Developments — Oruka Therapeutics, Inc.

Latest news

Generated 2026-05-20T20:21:21Z.

Thesis

Rewards
Recent Analyst detected in news
Risks
Concentration risk — Pipeline: ORKA-001 and ORKA-002
Concentration risk — Supplier: Paragon Therapeutics
Quality below floor (1.5 < 4.0)

Key Metrics

P/E (TTM)—
P/E (Fwd)-24.7
Mkt Cap$3.7B
EV/EBITDA-25.1
Profit Mgn0.0%
ROE-27.3%
Rev Growth—
Beta—
DividendNone
Rating analysts20

Quality Signals

Piotroski F4/9

Concentration Risks(10-K Item 1A)

  • HIGHpipelineORKA-001 and ORKA-002
    10-K Item 1A: 'We are substantially dependent on the success of our two most advanced programs, ORKA-001 and ORKA-002'
  • HIGHSupplierParagon Therapeutics
    10-K Item 1: 'We have entered into license agreements with Paragon pursuant to which Paragon granted us a royalty-bearing, world-wide, exclusive license'

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

2 floor-breakers·2 ceiling hits

Quality below the gate floor. Component breakdown shows what dragged the score down.static

Roe
0.0
Roa
0.0
Gross Margin
0.0
Operating Margin
0.0
Net Margin
0.0
Fcf Quality
0.0
Moat
4.0
Piotroski F
4.4
Current Ratio
5.0
Cash-burning (FCF negative)No competitive moatQuality concerns

Momentum below the gate floor. Component breakdown shows what dragged the score down.static

Macd
0.0
Obv
1.0
Volume
2.0
Ma Position
6.0
Rsi
8.1
Oversold in uptrend (RSI 28)Volume distribution (falling OBV)Above 200-day MA
GatesMomentum 3.4<4.5A.R:R 7.5 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS BOOST ANALYST 0.70EARNINGS PROXIMITY 84d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARSuitability: Aggressive
RSI
28 · Oversold
↓ 20D MA↑ 50D MA↑ 200D MAGOLDEN CROSSSupport $57.52Resistance $91.00

Price Targets

$56
$124
A.Upside+111.2%
A.R:R7.5:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeSteady

Risk Alerts

! Quality below floor (1.5 < 4.0)
! Momentum score 3.4/10 — below 4.5 minimum

Earnings

B
B
M
M
2/4 beats
Next Earnings2026-08-10 (84d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is ORKA stock a buy right now?

Sell if holding. Engine safety override at $58.56: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 7.5:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 18%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $55.79. Score 5.3/10, moderate confidence.

What is the ORKA stock price target?

Take-profit target: $123.69 (+112.0% upside). Prior stop was $55.79. Stop-loss: $55.79.

What are the risks of investing in ORKA?

Concentration risk — Pipeline: ORKA-001 and ORKA-002; Concentration risk — Supplier: Paragon Therapeutics; Quality below floor (1.5 < 4.0).

Is ORKA overvalued or undervalued?

Oruka Therapeutics, Inc. trades at a P/E of N/A (forward -24.7). TrendMatrix value score: 9.0/10. Verdict: Sell.

What do analysts say about ORKA?

20 analysts cover ORKA with a consensus score of 4.4/5. Average price target: $142.

What does Oruka Therapeutics, Inc. do?Oruka Therapeutics is a clinical-stage biopharmaceutical company developing extended half-life monoclonal antibodies...

Oruka Therapeutics is a clinical-stage biopharmaceutical company developing extended half-life monoclonal antibodies for psoriasis and other inflammatory conditions. Lead programs ORKA-001 (IL-23p19, Phase 2) and ORKA-002 (IL-17A/F, Phase 2) are licensed from Paragon Therapeutics; the company has no approved products and generates no product revenue.

Related stocks: AUPH (Aurinia Pharmaceuticals Inc) · INCY (Incyte Corporation) · ONC (BeOne Medicines Ltd.) · ADMA (ADMA Biologics Inc) · HALO (Halozyme Therapeutics, Inc.)